Celularity Names Fontaine Vitale as Strategic Partner for Bali Project in Q1 2027
Celularity Inc. has announced a strategic partnership related to Fontaine Vitale, a regenerative medicine and wellness center in Bali, Indonesia. The project, developed with Genting Berhad and Indonesian partners, targets an opening in the first quarter of 2027 and aims to serve local and international patients with advanced therapies and longevity-focused services.
What is changing with Fontaine Vitale
The company outlined progress toward opening Fontaine Vitale in the Sanur Special Economic Zone in Bali. The facility is described as a four-story, about 172,000-square-foot center that will offer placental-derived cellular therapies, regenerative medicine, aesthetics, and longevity services. Celularity positions this as a significant market and revenue opportunity in the Asia-Pacific region, with development led by Genting Berhad and Indonesian partners and input from Celularity.
Who is affected by the plan
Potential beneficiaries include patients in Bali and the broader ASEAN region seeking advanced wellness and regenerative therapies. The project may also affect local healthcare providers, suppliers, and regional partners involved in the development and operation of Fontaine Vitale. The announcement emphasizes international patients in addition to local clients.
Practical next steps or actions
For readers, useful steps include checking Fontaine Vitale’s official site for service offerings and confirmation of the January–March 2027 opening window. If you are considering care, consult with a licensed medical professional about the suitability of placenta-derived or regenerative therapies. Monitor updates from Celularity and Fontaine Vitale for regulatory details, availability, and pricing as the project progresses toward opening.
Limits, questions and context
The brief press notice describes a strategic partnership and an anticipated opening, but it does not provide detailed clinical evidence, safety data, or regulatory approvals specific to the Bali facility. Readers should look for additional sources for medical efficacy, patient eligibility, and local regulatory status as the project evolves.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- biospace.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.